

Balancing clinical benefits and behavioral risks of obesity-focused management in youth-onset type 2 diabetes: A narrative review

Rutha Chivate,¹ Caroline Christian,² Abigail Hartman,³ Afsana Dhali,⁴ Andrea B Goldschmidt² and Mary Ellen Vajravelu⁵

1. University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 2. Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 3. Diabetes Wraparound Program, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA; 4. University of Pittsburgh, Pittsburgh, PA, USA; 5. Department of Pediatrics, Division of Pediatric Endocrinology and Center for Pediatric Obesity and Metabolism, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

<https://doi.org/10.17925/EE.2026.22.2.6>

Weight management is a key treatment goal for youth-onset type 2 diabetes, a condition that is strongly linked with obesity. For this reason, glucagon-like peptide-1 (GLP-1) receptor agonists, with their glycemic- and weight-reducing effects, have been increasingly used in adolescents and young adults with type 2 diabetes. However, because disordered eating behaviors and eating disorders are also relatively common in this population, use of appetite-suppressing medications such as GLP-1 may have unintended psychological or behavioral consequences. In this narrative review, we summarize the epidemiology of disordered eating behaviors and eating disorders among youth with type 2 diabetes and the limited evidence related to disordered eating and GLP-1 use. We end with suggested strategies for clinicians to identify and care for youth with disordered eating behaviors or eating disorders in the context of type 2 diabetes. Future research should prioritize the creation and validation of a disordered eating screener that is appropriate for youth with type 2 diabetes undergoing medical weight management, as well as identify factors associated with positive versus negative eating behavior responses to GLP-1.

Keywords

Diabetes mellitus, type 2, diagnostic screening programs, feeding and eating disorders, glucagon-like peptide 1 receptor agonists (GLP-1 RA), obesity, pediatrics

Disclosures: Rutha Chivate received T35 Grant (DK065521) from the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, March 2023, and the Student Research Program Conference Award, May 2024 from the University of Pittsburgh School of Medicine and the Graduate and Professional Student Government Travel Grant, May 2024 from the University of Pittsburgh. Caroline Christian has received support from the National Heart, Lung and Blood Institute under T32 HL07560 (PI: Thurston). Andrea Goldschmidt has received R01-HL147914, R01-DK136540, R01DK137803, Metis Foundation/US Department of Defense grant I80VP000653, University of Pittsburgh School of Medicine Pediatric Health Equity Award, R13-HS029603, R34MH123589, R01-MH124832, R01DK120597 and receives royalties from Routledge Publishing, support for attending meetings and/or travel from the University of New South Wales, Israel Academy for Eating Disorders and the Daimler-Benz Foundation. She has participated on the data safety monitoring board for R34-MH126965. Mary Ellen Vajravelu is a coinvestigator in clinical trials sponsored by Novo Nordisk and Lilly but does not receive any personal remuneration, effort support or direct funding. She has received payments to her institution from the National Institutes of Health, the Shear Family Foundation, the Pittsburgh Foundation, the UPMC Children's Hospital of Pittsburgh and the RK Mellon Institute of UPMC Children's Hospital of Pittsburgh. She has received payment as the Bacon Lecturer from the University of Michigan. Abigail Hartman and Afsana Dhali have no financial or non-financial relationships or activities to declare in relation to this article.

Acknowledgements: We thank research librarian Rebekah Miller for her assistance with the literature review for this manuscript. No artificial intelligence (AI) or large language model (LLM) tools were used in the development of this article.

Review process: Double-blind peer review.

Compliance with ethics: This article involves a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors.

Data availability: Data sharing is not applicable to this article as no datasets were generated or analyzed during the writing of this article.

Authorship: All named authors meet the criteria of the International Committee of Medical Journal Editors for authorship for this manuscript, take responsibility for the integrity of the work as a whole and have given final approval for the version to be published.

Access: This article is freely accessible at [touchENDOCRINOLOGY.com](https://touchendocrinology.com). ©Touch Medical Media 2026.

Received: 8 May 2026

Accepted: 30 July 2026

Published online: 14 October 2026

Citation: *touchREVIEWS in Endocrinology*. 2026;20(2):Online ahead of journal publication

Corresponding author: Mary Ellen Vajravelu, Division of Pediatric Endocrinology and Center for Pediatric Obesity and Metabolism, Department of Pediatrics, University of Pittsburgh School of Medicine, Rangos Research Center, 4401 Penn Ave, 3501B, Pittsburgh, PA 15224, USA.
E: vajravelume@upmc.edu, vajravelu@pitt.edu

Support: This work was supported in part by the Shear Family Foundation. Dr Goldschmidt and Dr Vajravelu receive funding from the National Institutes of Health that is unrelated to this work. Dr Christian's time was supported by the National Heart, Lung, and Blood Institute under T32 HL07560 (PI: Thurston). This funding source had no role in the study design, data collection, interpretation of the data, or decision to write and publish the manuscript. The content of this manuscript does not necessarily represent the official views of the National Institutes of Health. No funding was received in the publication of this article.

Youth-onset type 2 diabetes is increasingly common in the USA, with incidence exceeding that of type 1 diabetes among 15–19-year-old adolescents and prevalence projected to increase by 673% by 2060.^{1,2} This growth is particularly worrisome due to the severity of youth-onset type 2 diabetes, which is more aggressive than adult-onset type 2 diabetes and carries a high risk of comorbid hypertension, dyslipidemia and diabetic kidney disease in young adulthood.³ One major risk factor for type 2 diabetes is pediatric obesity, defined as body mass index (BMI) ≥ 95 th percentile for age and sex. At the time of type 2 diabetes diagnosis, approximately 80% of youth have obesity, which carries an increased risk of cardiovascular and kidney disease above and beyond a diagnosis of type 2 diabetes alone.^{4–6} Obesity management is, therefore, a key goal of type 2 diabetes care, including both healthy lifestyle changes and careful medication selection to optimize glycemic and weight outcomes.⁷ Glucagon-like peptide-1 (GLP-1) receptor agonists, which were originally developed to support glycemic control, also have robust beneficial effects on weight, unlike metformin and insulin. Indeed, given their positive glycemic- and weight-lowering effects, there have been calls to alter guidelines to prioritize early combination therapy including GLP-1 as first-line therapy for youth with type 2 diabetes.⁸

Currently, four different GLP-1 medications have been approved by the U.S. Food and Drug Administration for use in youth with type 2 diabetes (liraglutide, exenatide, dulaglutide, and tirzepatide – a dual GLP-1 and glucose-dependent insulinotropic polypeptide [GIP] agonist).^{9–12} Semaglutide is approved for weight management in youth with obesity, and a recent clinical trial demonstrated glycemic efficacy in youth with type 2 diabetes as well.¹³ While average BMI reduction varies by formulation, tirzepatide results in the greatest reduction (15.1% BMI reduction at 1 year) relative to other formulations approved for type 2 diabetes, although head-to-head pediatric trials are lacking.¹² Uptake of GLP-1 has been increasing, with more than one-third of youth with type 2 diabetes having a GLP-1 dispensed to them in 2023, among both Medicaid- and commercially insured youth.¹⁴

Despite the enthusiasm for glycemic- and weight-related efficacy of GLP-1, very little is known about their impact on disordered eating behaviors or risk of eating disorders.¹⁵ Eating disorders are serious, neurobiologically based psychiatric illnesses characterized by disordered eating behaviors, distorted cognitions around food, eating and body shape/weight, and oftentimes, difficulties with weight regulation.¹⁶ Even in the absence of meeting full diagnostic criteria for an eating disorder, subthreshold disordered eating behaviors cause significant distress and impairment and can be associated with the same medical risks and consequences as full-syndrome disease states.^{17,18} In this narrative review, we summarize the epidemiology, outcomes, and assessment of disordered eating behaviors and eating disorders in the context of youth-onset type 2 diabetes, with specific attention to evidence related to GLP-1 use whenever possible based on the current literature. We end with a summary of evidence gaps and future directions for research and clinical care.

Methods

A literature search of PubMed and PsycInfo databases was completed in December 2025 with assistance from a research librarian and updated in April 2026. For PubMed, the following search query was used: (((‘Diabetes Mellitus, Type 2’[Mesh]) OR ‘type two [sic] diabetes’ OR ‘Obesity’[Mesh]) AND ((‘Pediatrics’[Mesh]) OR ‘Adolescent’[Mesh] OR ‘teenager’)) AND (((‘Metformin’[Mesh]) OR ‘Phentermine’[Mesh]) OR ‘Sodium-Glucose Transporter 2 Inhibitors’[Mesh]) OR ‘Glucagon-Like Peptide-1 Receptor Agonists’[Mesh]) OR ‘Insulin’[Mesh] AND ((‘Disordered Eating

Behavior’[Mesh]) OR ‘Feeding and Eating Disorders’[Mesh] OR ‘eating disorder’). For PsycInfo, the search query included: ‘disordered eating’ or ‘Eating Disorders’ and ‘Pediatrics’ or ‘adolescent’ and ‘Type 2 Diabetes’ or ‘Obesity’ or ‘Childhood Obesity.’ This generated 495 references from PsycInfo and 418 references from PubMed. Initial review of the reference title and abstract was divided across all authors. References were considered for inclusion if they were written in English and addressed disordered eating behaviors or eating disorders (‘disordered eating,’ ‘binge eating’ or ‘eating disorder’) among youth (ages 12–18) with type 2 diabetes. If there was uncertainty about eligibility, the full text was reviewed, and inclusion or exclusion was determined by consensus among all authors. Of the 11 manuscripts identified for full-text review, 7 were included; excluded manuscripts were reviews without a focus on disordered eating or eating disorders (n=3) and a study unrelated to youth-onset type 2 diabetes (n=1).^{19–25} One additional manuscript identified via the systematic review of disordered eating behaviors and eating disorders in youth with type 2 diabetes by Mateo et al. was included.^{25,26}

Prevalence and consequences of eating disorders and disordered eating behavior in individuals with type 2 diabetes


Among youth and young adults with type 2 diabetes, the prevalence of disordered eating behaviors has been estimated to be as high as 50%, compared with a prevalence of 21% among youth and young adults with type 1 diabetes.¹⁹ In the population-based prospective SEARCH for Diabetes in Youth cohort, youth with type 2 diabetes with disordered eating behaviors (versus without) were found to have higher BMI, lower quality of life and more depressive symptoms, as well as more severe experiences of diabetes stigma.^{19,20} The SEARCH for Diabetes in Youth study also demonstrated that disordered eating behaviors were associated with food insecurity among youth with type 2 diabetes, with a gradient of higher scores on the Diabetes Eating Problem Survey-Revised (DEPS-R) in the setting of more severe food insecurity.^{20,21} While full-syndrome eating disorders have been less thoroughly studied in the context of pediatric type 2 diabetes, the prevalence of binge-eating disorder has been estimated to be as high as 25% in adults with type 2 diabetes.²⁷ A higher risk of type 2 diabetes among individuals with eating disorders has also been described, with adults with binge-eating disorder or bulimia nervosa having a higher lifetime prevalence of type 2 diabetes versus adult peers without eating disorders (5.2% versus 1.7%), suggesting a bidirectional relationship.²⁸

For adolescents with type 2 diabetes, disordered eating behaviors are associated with poor glycemic control, increasing the risk of diabetes-related complications. One factor contributing to worsened glycemic control is insulin restriction, which is more prevalent in individuals with type 1 diabetes but has also been observed in those with type 2 diabetes.¹⁹ Furthermore, dysregulated glucose metabolism can contribute to the onset of binge-type eating behaviors as seen in binge-eating disorder and bulimia nervosa, which can then worsen complications in a positive feedback loop.²⁸ Individuals with disordered eating behaviors are also more likely to experience depressive symptoms, adding to the already high risk of depression for adolescents with type 2 diabetes.^{19,29–31}

Prevalence and consequences of eating disorders and disordered eating behavior in higher-weight youth

Obesity is pervasive among youth with type 2 diabetes, and disordered eating behaviors with or without a formal eating disorder diagnosis are more common among higher-weight youth than their lower-weight

Figure 1: Conceptual model depicting biological, behavioral and psychosocial processes by which obesity, binge eating and type 2 diabetes are related



Boxes with thicker lines indicate outcomes impacted by glucagon-like peptide-1 (GLP-1) receptor agonists, with thicker solid lines representing known impacts and thicker dashed lines representing putative impacts requiring further study

peers.^{4,5,32} This likely emerges from shared risk factors for obesity and disordered eating, including dieting, experiences of weight-related stigma and body dissatisfaction.³³ Binge and loss of control eating, characterized by the subjective experience of being unable to control what or how much one is eating with or without ingestion of an objectively large amount of food, respectively, are particularly prevalent among youth with overweight and obesity, occurring in 26.3% across 36 studies included in a meta-analysis.³⁴

The high prevalence of eating disorder symptoms among individuals with higher weight (with or without type 2 diabetes) may be attributed to a variety of risk factors specific to this population, including family history, environmental factors, weight stigma, weight-related teasing, internalized weight bias, increased dieting attempts and weight cycling.^{35–38} Engaging in restrictive dieting behaviors is one of the strongest risk factors for eating disorders among higher-weight youth and is highly relevant among youth with type 2 diabetes and obesity, whose treatment goals may include dietary restriction for both weight loss and glycemic control.³⁶ For example, recommendations to manage diet, such as reducing intake of high-carbohydrate foods, may increase feelings of deprivation among vulnerable youth, thereby contributing to further binge eating (Figure 1). However, while weight control efforts by adolescents have been linked with higher eating disorder risk, medically supervised weight management interventions may in fact be protective.³⁹ A scoping review of 126 behavioral intervention trials including children and adolescents with overweight and obesity found that psychosocial outcomes generally improved or remained unchanged in the intervention arm as compared with controls, although the data were limited by significant heterogeneity in assessments.³⁹

Evaluating and addressing risk for disordered eating behaviors and eating disorders among youth with type 2 diabetes

There are a few validated screening tools for detecting eating disorder risk in youth with normal or high BMI, with screeners often administered to youth who are already showing major physical signs or symptoms of eating disorders, such as rapid weight loss or gain, pubertal delay, pronounced deviation from the growth curve, bradycardia or irregular menstruation.³⁸ Existing screening tools are limited by a focus on a finite set of symptoms (e.g. symptoms of restrictive eating or binge eating, but not both). They are also validated primarily among females with low weight and not in racially or ethnically diverse youth (a gap

that is particularly relevant in youth-onset type 2 diabetes, which is least common among non-Hispanic White youth).⁴⁰ Diabetes-specific screeners place an emphasis on the use of insulin, which is not universal among youth with type 2 diabetes. Currently validated assessment tools are lengthy, complex to score, do not generate diagnoses and require training to administer, so they are not feasible for use as screening tools.

Table 1 provides a summary of disordered eating assessment methods used in prior studies, including youth with type 2 diabetes, as well as examples of screening tools used for youth with type 1 diabetes or obesity. Disordered eating assessment methods for youth with type 2 diabetes in prior studies included: DEPS-R, which was validated in adolescents with type 1 diabetes and is more appropriate for youth using insulin; questions from the Youth Risk Behavior Surveillance System (YRBSS), not a formal screening tool, with a focus on weight management worries, goals and attempts; the Youth-Eating Disorder Examination Questionnaire (Y-EDEQ), which evaluates restraint and eating, weight and shape concerns; and the Eating Disorder Diagnostic Scale (EDDS), which assesses attitudinal symptoms of anorexia nervosa and bulimia nervosa, as well as episodes of uncontrollable consumption of large amounts of food and compensatory behaviors.^{26,41–44} For comparison, one survey validated for use in youth with type 1 diabetes (mSCOFF [modified SCOFF]) and two for use in adolescents with obesity but without diabetes (Adolescent Binge Eating Scale [ADO-BED] and Children's Brief Binge-Eating Questionnaire [CBBEQ]) are also included in Table 1.^{19,22–24,26,41–48} As shown in the table, modifications and additional studies would be required to ensure these screening tools are appropriate for youth with type 2 diabetes, who may use a variety of medication regimens that affect appetite and/or weight, including metformin, insulin and GLP-1.

In addition to the appropriateness of a given tool, another important consideration when screening for eating disorders is the availability of specialized care to which clinicians can refer as needed. Most clinicians who have not sought specialized training in eating disorder treatment have limited comfort and ability to recognize and manage eating disorder symptoms.^{49,50} Furthermore, the lack of referral options and expert consultants in many communities, fear of introducing iatrogenic effects or stigmatizing patients and limited self-efficacy lead many providers to avoid asking questions about eating behaviors or weight at all.⁵¹ Thus, while validated and easily disseminated screening

Table 1: Limitations of existing questionnaires previously used to assess disordered eating among youth with type 2 diabetes, type 1 diabetes and obesity^{19,22-24,26,41-48}

Questionnaire	Details	Evidence in pediatric type 2 diabetes	Limitations for use in type 2 diabetes
DEPS-R ⁴¹	16-item survey Validated in adolescents with type 1 diabetes Assesses the frequency of behaviors in the past month Includes items related to ketones and insulin use	50.3% of TODAY study participants (adolescents with recently diagnosed type 2 diabetes) had elevated scores ≥ 20 ¹⁹	Limited relevance to youth not using insulin and at lower risk for ketosis or ketoacidosis Losing weight may be an appropriate goal in the setting of obesity
YRBSS, ⁴² adapted ²⁶	Subset of a larger survey of behaviors, not a true screening tool Descriptive, not validated for detection of eating disorders Assesses self-perception and worry about weight, weight management goals and weight loss attempts	Females with type 2 diabetes are more likely than females with type 1 diabetes to engage in maladaptive eating behaviors, including fasting or using diet aids such as pills without a doctor's advice ²⁶	Does not include items about the use of doctor-prescribed medication for weight management No cutoff for detection and referral for evaluation of eating disorders
Y-EDEQ ⁴³	39-item survey Assesses restraint, eating concern, weight concern and shape concern Subclinical binge eating defined as reporting 1–3 episodes in the past month and clinical binge eating defined as ≥ 4 episodes	At baseline, 6% of youth enrolled in the TODAY study had clinical binge eating and 20% had subclinical levels of binge eating, associated with extreme obesity, depressive symptoms and impaired quality of life ²³ Subclinical binge eating in parents was associated with subclinical binge eating in adolescents in the TODAY study at baseline ²²	Some items (e.g. 'definite rules regarding your eating' and 'Has thinking about food... made it very difficult to concentrate...') may be difficult to interpret in the setting of dietary recommendations for diabetes Low accuracy for detecting loss of control eating in younger children with overweight/obesity
EDDS ⁴⁴	23-item survey Assesses attitudinal symptoms of anorexia nervosa and bulimia nervosa over the past 3-month period, frequency of uncontrollable consumption of a large amount of food and frequency of compensatory behaviors	Binge eating present in 10% of youth in the TODAY study at baseline and stable over longitudinal follow-up; diagnosable eating disorder (e.g. binge-eating disorder) present in 1.4% at baseline ²⁴	Insulin underdosing or omission not specified in EDDS
mSCOFF ^{45,46}	5-item survey, with the fifth item modified from the original to assess insulin omission Validated among adolescents with type 1 diabetes	None	Not relevant for youth not using insulin Potential appropriateness of recent weight loss among higher-weight youth not considered
ADO-BED ⁴⁷	6-item survey (with subitems) to evaluate binge eating in adolescents Initially evaluated in adolescents seeking obesity management	None	Nothing specific to living with diabetes Eating while not hungry may be necessary in the setting of hypoglycemia
CBBEQ ⁴⁸	7-item survey to evaluate hunger, binge eating and loss of control eating Initially evaluated in adolescents seeking obesity management	None	Nothing specific to living with diabetes Eating while not hungry may be necessary in the setting of hypoglycemia

TODAY: Treatment Options for type 2 Diabetes in Adolescents and Youth; ClinicalTrials.gov identifier: NCT00081328

ADO-BED = Adolescent Binge Eating Scale; CBBEQ = Children's Brief Binge-Eating Questionnaire; DEPS-R = Diabetes Eating Problem Survey-Revised; EDDS = Eating Disorder Diagnostic Scale; mSCOFF = modified SCOFF ED Screening Questionnaire; TODAY = Treatment Options for type 2 Diabetes in Adolescents and Youth; Y-EDEQ = Youth-Eating Disorder Examination Questionnaire; YRBSS = Youth Risk Behavior Surveillance System.

tools are needed for this population, this should be paired with training for clinicians and facilitated referral processes.

Disordered eating behaviors or eating disorders in the setting of glucagon-like peptide-1 use for type 2 diabetes or obesity management

Due to GLP-1-induced changes in appetitive processes such as food cue reactivity, hunger, satiety and cravings, all of which are putative mechanisms underlying dysregulated eating behaviors, it is possible that some forms of maladaptive eating, such as binge-type eating, may improve with GLP-1 use.^{52,53} While early evidence in adults using GLP-1 suggests improved or unchanged disordered eating behaviors, with lower binge eating prevalence associated with semaglutide and fewer binge episodes with liraglutide, effects of these medications on disordered eating are extremely limited overall and non-existent in children.^{15,54,55} There is similarly little empirical evidence on the effects of GLP-1 use on restrictive eating behaviors; however, it is also possible that medication-induced changes in these same appetitive processes could support increased dietary restriction.⁵⁶ Furthermore, in line with theoretical models drawn from the eating disorders literature, rapid and large changes in body weight/size accompanied by external validation from peers, providers and/or family members may heighten appearance-related concerns and fear of weight regain, thus reinforcing potential restrictive eating behaviors.⁵⁷

Based on these potential impacts, evidence to clarify the relationship between GLP-1 use and disordered eating behaviors or eating disorders

is critically needed and widely sought. For example, in a nationwide survey, U.S. adolescents and young adults shared concerns that GLP-1 use could contribute to eating disorder risk, as well as their desire for more safety information.⁵⁸ Similarly, pediatric primary care clinicians were less willing to prescribe anti-obesity medications such as GLP-1 to youth exhibiting signs and symptoms concerning for disordered eating.⁵⁹ Finally, in a qualitative study of adolescents and young adults using or planning to use anti-obesity medications including GLP-1, as well as their caregivers, experiences related to disordered eating were variable, with one young adult sharing that she had become 'addicted to weight loss' after starting the medication. However, others shared positive experiences, noting medication use had resolved pre-existing binge eating and restriction behaviors, and had improved their relationships with food.⁶⁰ Ultimately, the current evidence related to GLP-1 use and disordered eating behaviors or eating disorders in youth remains extremely limited and heterogeneous.

Table 2 summarizes the medication regimens of participants in the included studies of youth with type 2 diabetes who responded to disordered eating questionnaires.^{19-24,26} Due in part to the more recent U.S. Food and Drug Administration approval of GLP-1 for pediatric use (liraglutide for type 2 diabetes in 2019), none explicitly commented on the use of GLP-1 by participants, and insulin use was variable or not specified. While some studies noted that insulin omission may be used to promote unhealthy weight loss, others did not specifically discuss the potential for medications to affect appetite, dietary intake, disordered eating or weight.^{19-24,26}

Table 2: Medication regimens of participants in included studies evaluating disordered eating in youth with type 2 diabetes^{19–24,26}

First author (year)	Population	Disordered eating measure	Medication regimen(s)	Discussion of medication(s) in relation to appetite, dietary intake, disordered eating or weight?
Lawrence (2008) ²⁶	SEARCH for Diabetes in Youth Study: youth and young adults with type 1 and type 2 diabetes; minority (519 [15.5%]) with type 2 diabetes	YRBSS, modified	38% of females and 34% of males used insulin	Insulin omission as a strategy to promote unhealthy weight loss Using diet aids more common among youth with type 2 diabetes than type 1 diabetes
TODAY Study Group (2011) ²³	TODAY study: youth with recently diagnosed type 2 diabetes	Y-EDEQ	Metformin only	No
Weinstock (2015) ²²	TODAY study: youth with recently diagnosed type 2 diabetes	Y-EDEQ	Distribution of metformin alone, metformin and rosiglitazone and/or insulin not specified	No
Nip (2019) ¹⁹	SEARCH for Diabetes in Youth Study: youth and young adults with type 1 and type 2 diabetes; minority (149 [6.5%]) with type 2 diabetes	DEPS-R	All using insulin, due to the DEPS-R question about insulin omission	Insulin omission as a strategy to promote unhealthy weight loss
Eitel (2024) ²⁰	SEARCH for Diabetes in Youth Study: youth and young adults with type 1 and type 2 diabetes; minority (353 [22%]) with type 2 diabetes	DEPS-R	Not noted	No
TODAY Study Group (2022) ²⁴	TODAY study: youth with recently diagnosed type 2 diabetes	EDDS	Distribution of metformin alone, metformin and rosiglitazone and/or insulin not specified	Noted that insulin omission as a strategy to promote unhealthy weight loss was not assessed
Julceus (2025) ²¹	SEARCH for Diabetes in Youth Study: youth and young adults with type 1 and type 2 diabetes; minority (395 [14.8%]) with type 2 diabetes	DEPS-R	Not noted	Insulin or oral hypoglycemic drug omission as a strategy to promote unhealthy weight loss Glucagon-like peptide-1 receptor agonists not mentioned

Note: All studies except for Eitel et al. and Julceus et al. included data collected prior to the first U.S. Food and Drug Administration approval of glucagon-like peptide-1 receptor agonists for youth (liraglutide in 2019).

DEPS-R = Diabetes Eating Problem Survey-Revised; EDDS = Eating Disorder Diagnostic Scale; TODAY = Treatment Options for type 2 Diabetes in Adolescents and Youth; Y-EDEQ = Youth-Eating Disorder Examination Questionnaire; YRBSS = Youth Risk Behavior Surveillance System.

Clinical strategies to minimize harms related to disordered eating behaviors and eating disorders in youth with type 2 diabetes

Given the current very sparse evidence base, it is conservative but reasonable to assume that youth seeking and using GLP-1 for type 2 diabetes management are at increased risk for disordered eating due to the guideline-recommended emphasis on weight management as a key aspect of type 2 diabetes treatment.⁶¹ Until a validated screener for this population is available, providers should remain cognizant of signs or patterns of disordered eating behaviors that may emerge. It is important to note that such patterns may closely resemble the normative response to treatment but may be greater in pace or magnitude, such as losing weight more quickly than recommended, the inability to stop losing weight once a target weight is reached, engaging in dieting that becomes progressively more restrictive over time, food avoidance without medical, ethical or cultural reason, regularly skipping meals, becoming preoccupied with eating and sudden and extreme changes in exercise behavior.⁶² Other symptoms and behaviors that should raise concern for eating disorders include feeling a loss of control over what or how much is eaten, vomiting for shape or weight reasons and laxative or diuretic use. Providers are encouraged to monitor disordered eating symptoms before GLP-1 initiation, regularly throughout treatment and after discontinuation using validated screening tools such as the EDDS or mSCOFF, while recognizing that these tools may not detect the full spectrum of risk for disordered eating among youth with type 2 diabetes, including those using GLP-1 medications, and may require supplemental assessment. New onset or worsening symptoms should signal more intensive monitoring and/or referral to a specialty provider for comprehensive evaluation.

One important way to support youth at risk for disordered eating is to minimize exposure to medical weight stigma, which has been shown to be

associated with negative health outcomes across several domains, including elevated risk for eating disorder symptoms.^{63,64} Even well-intentioned providers may perpetuate weight stigma when caring for patients with overweight or obesity, especially in the context of providing weight management recommendations. Clinicians should practice awareness of their own biases around weight and the ways in which weight stigma manifests to provide high-quality assessment and care to individuals with higher weight.⁶² For all patients, personalized and collaborative goal-setting on health- and weight-related goals can be protective against the risk of eating disorders. We advise patient education about the harms of misusing GLP-1 (e.g. on-going GLP-1 use despite severe gastrointestinal side effects or appetite suppression that leads to prolonged fasting) and omitting insulin (i.e. worsening glycemic control, diabetic ketoacidosis). Lastly, consistent with clinical practice guidelines, clinicians should collaborate with dietitians and therapists in caring for youth with type 2 diabetes.⁷ Similarly, clinicians specializing in eating disorder treatment may benefit from support from the clinical diabetes team to understand the potential weight- and appetite-altering effects of medications, as well as dietary guidelines for type 2 diabetes management.

Conclusion

Although further studies are needed, current evidence suggests that disordered eating behaviors are common in adolescents with type 2 diabetes, a risk that may be exacerbated by a strict focus on weight reduction as a treatment goal. More data are needed to understand the risks and benefits posed by the use of GLP-1 in this population, particularly related to disordered eating risk. Given the lack of validated screening tools for youth with type 2 diabetes and the serious consequences associated with unrecognized disordered eating, clinicians should be aware of the higher risk of disordered eating behaviors and eating disorders in this population, as well as the need to monitor for changes in behaviors during the use of GLP-1. □

1. Tönnes T, Brinks R, Isom S, et al. Projections of type 1 and type 2 diabetes burden in the U.S. population aged <20 years through 2060: The SEARCH for diabetes in youth study. *Diabetes Care*. 2023;46:313–20. DOI: 10.2337/dc22-0945.
2. Wagenknecht LE, Lawrence JM, Isom S, et al. Trends in incidence of youth-onset type 1 and type 2 diabetes in the USA, 2002–18: Results from the population-based SEARCH for diabetes in youth study. *Lancet Diabetes Endocrinol*. 2023;11:242–50. DOI: 10.1016/S2213-8587(23)00025-6.
3. Bjornstad P, Drews K, Zeitler P. Long-term complications in youth-onset type 2 diabetes. *N Engl J Med*. 2021;385:2014–6. DOI: 10.1056/NEJMc2114053.
4. Cloana M, Deng J, Nadarajah A, et al. The prevalence of obesity among children with type 2 diabetes: A systematic review and meta-analysis. *JAMA Netw Open*. 2022;5:e2247186. DOI: 10.1001/jamanetworkopen.2022.47186.
5. Hoyek K, Libman I, Mkpuru N, et al. Child opportunity index and clinical characteristics at diabetes diagnosis in youth: Type 1 diabetes versus type 2 diabetes. *BMJ Open Diabetes Res Care*. 2024;12:e003968. DOI: 10.1136/bmjdc-2023-003968.
6. American Diabetes Association Professional Practice Committee for Diabetes. 8. Obesity and weight management for the prevention and treatment of diabetes: Standards of care in diabetes—2026. *Diabetes Care*. 2026;49:S166–82. DOI: 10.2337/dc26-S008.
7. Diabetes* ADAPPCf. 14. Children and adolescents: Standards of care in diabetes—2026. *Diabetes Care*. 2026;49:S297–320. DOI: 10.2337/dc26-S014.
8. Chung ST, Davis F, Patel T, et al. Reevaluating first-line therapies in youth-onset type 2 diabetes. *J Clin Endocrinol Metab*. 2024;109:e870–2. DOI: 10.1210/clinem/dgaa508.
9. Arslanian SA, Hannon T, Zeitler P, et al. Once-weekly dulaglutide for the treatment of youths with type 2 diabetes. *N Engl J Med*. 2022;387:433–43. DOI: 10.1056/NEJMoa2204601.
10. Tamborlane WV, Barrientos-Pérez M, Fainberg U, et al. Liraglutide in children and adolescents with type 2 diabetes. *N Engl J Med*. 2019;381:637–46. DOI: 10.1056/NEJMoa1903822.
11. Tamborlane WV, Bishai R, Geller D, et al. Once-weekly exenatide in youth with type 2 diabetes. *Diabetes Care*. 2022;45:1833–40. DOI: 10.2337/dc21-2275.
12. Hannon TS, Chao LC, Barrientos-Pérez M, et al. Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): A randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2025;406:1484–96. DOI: 10.1016/S0140-6736(25)01774-X.
13. Novo Nordisk A/S. Novo Nordisk's oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes. 2026. Available at: <https://ml-eu.globenewswire.com/Resource/Download/15e12887-66a3-49ed-bc80-56e4a1d211fe> (accessed: 23 April 2026).
14. Chu PY, Kelly A, Hennessy S, et al. GLP-1RA dispensing in youth with type 2 diabetes: 2020 to 2023. *Pediatrics*. 2026;157:e2025071971. DOI: 10.1542/peds.2025-071971.
15. Bartkoski M, Poweleit EA, Stancil SL. GLP-1 agonists for pediatric psychopharmacology: Opportunities and cautions. *Clin Transl Sci*. 2025;18:e70262. DOI: 10.1111/cts.70262.
16. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 5th ed. American Psychiatric Association, 2013.
17. Hammerle F, Huss M, Ernst V, Bürger A. Thinking dimensional: Prevalence of DSM-5 early adolescent full syndrome, partial and subthreshold eating disorders in a cross-sectional survey in German schools. *BMJ Open*. 2016;6:e010843. DOI: 10.1136/bmjopen-2015-010843.
18. Stice E, Marti CN, Shaw H, Jaconis M. An 8-year longitudinal study of the natural history of threshold, subthreshold, and partial eating disorders from a community sample of adolescents. *J Abnorm Psychol*. 2009;118:587–97. DOI: 10.1037/a0016481.
19. Nip ASY, Reboussin BA, Dabelea D, et al. Disordered eating behaviors in youth and young adults with type 1 or type 2 diabetes receiving insulin therapy: The SEARCH for diabetes in youth study. *Diabetes Care*. 2019;42:859–66. DOI: 10.2337/dc18-2420.
20. Eitel KB, Roberts AJ, D'Agostino R Jr, et al. Diabetes stigma and psychosocial outcomes in adolescents and young adults: The SEARCH for diabetes in youth study. *Diabetes Care*. 2024;47:290–4. DOI: 10.2337/dc23-1453.
21. Julceus EF, Liese AD, Alfalki AM, et al. The association of levels of food insecurity and disordered eating behaviors among youth and young adults with diabetes: The SEARCH for Diabetes in Youth study. *Int J Eat Disord*. 2025;58:1039–47. DOI: 10.1002/eat.24411.
22. Weinstock RS, Trief PM, El Ghormli L, et al. Parental characteristics associated with outcomes in youth with type 2 diabetes: Results from the TODAY clinical trial. *Diabetes Care*. 2015;38:784–92. DOI: 10.2337/dc14-2393.
23. Today Study Group, Wilfley D, Berkowitz R, et al. Binge eating, mood, and quality of life in youth with type 2 diabetes: Baseline data from the TODAY study. *Diabetes Care*. 2011;34:858–60. DOI: 10.2337/dc10-1704.
24. Today Study Group. Longitudinal association of depressive symptoms, binge eating, and quality of life with cardiovascular risk factors in young adults with youth-onset type 2 diabetes: The TODAY2 study. *Diabetes Care*. 2022;45:1073–81. DOI: 10.2337/dc21-1995.
25. Mateo K, Greenberg B, Valenzuela J. Disordered eating behaviors and eating disorders in youth with type 2 diabetes: A systematic review. *Diabetes Spectr*. 2024;37:342–8. DOI: 10.2337/ds23-0064.
26. Lawrence JM, Liese AD, Liu L, et al. Weight-loss practices and weight-related issues among youth with type 1 or type 2 diabetes. *Diabetes Care*. 2008;31:2251–7. DOI: 10.2337/dc08-0719.
27. Winston AP. Eating disorders and diabetes. *Curr Diab Rep*. 2020;20:32. DOI: 10.1007/s11892-020-01320-0.
28. Raevuori A, Suokas J, Haukka J, et al. Highly increased risk of type 2 diabetes in patients with binge eating disorder and bulimia nervosa. *Int J Eat Disord*. 2015;48:555–62. DOI: 10.1002/eat.22334.
29. Niemelä PE, Leppänen HA, Voutilainen A, et al. Prevalence of eating disorder symptoms in people with insulin-dependent diabetes: A systematic review and meta-analysis. *Eat Behav*. 2024;53:101863. DOI: 10.1016/j.eatbeh.2024.101863.
30. Wang X, You S, Tang S, et al. Depression comorbidity in children and adolescents with type 2 diabetes mellitus: A systematic review and meta-analysis. *Front Endocrinol*. 2026;17:1782080. DOI: 10.3389/fendo.2026.1782080.
31. Gulley LD, Shomaker LB. Depression in youth-onset type 2 diabetes. *Curr Diab Rep*. 2020;20:51. DOI: 10.1007/s11892-020-01334-8.
32. López-Gil JF, García-Hermoso A, Smith L, et al. Global proportion of disordered eating in children and adolescents: A systematic review and meta-analysis. *JAMA Pediatr*. 2023;177:363–72. DOI: 10.1001/jamapediatrics.2022.5848.
33. Haines J, Neumark-Sztainer D. Prevention of obesity and eating disorders: A consideration of shared risk factors. *Health Educ Res*. 2006;21:770–82. DOI: 10.1093/her/cyl094.
34. He J, Cai Z, Fan X. Prevalence of binge and loss of control eating among children and adolescents with overweight and obesity: An exploratory meta-analysis. *Int J Eat Disord*. 2017;50:91–103. DOI: 10.1002/eat.22661.
35. Leme ACB, Haines J, Tang L, et al. Impact of strategies for preventing obesity and risk factors for eating disorders among adolescents: A systematic review. *Nutrients*. 2020;12:3134. DOI: 10.3390/nu12103134.
36. Jebelle H, Lister NB, Baur LA, et al. Eating disorder risk in adolescents with obesity. *Obes Rev*. 2021;22:e13173. DOI: 10.1111/obr.13173.
37. Nagata JM, Thompson A, Helmer CK, et al. Weight discrimination and eating disorder symptoms in early adolescence: A prospective cohort study. *J Eat Disord*. 2025;13:216. DOI: 10.1186/s40337-025-01404-w.
38. Londoño-Pérez C, Moreno Ruge AM. Family and personal predictors of eating disorders in young people. *An Psicol*. 2017;33:235–42. DOI: 10.6018/analesps.33.2.236781.
39. Kwok C, Sacco S, Lister NB, et al. Changes in psychosocial outcomes reported in behavioral intervention trials for children and adolescents with overweight and obesity: A scoping review. *Child Obes*. 2026;22:187–205. DOI: 10.1177/21532176261418755.
40. Divers J, Mayer-Davis EJ, Lawrence JM, et al. Trends in incidence of type 1 and type 2 diabetes among youths - Selected counties and Indian reservations, United States, 2002–2015. *MMWR Morb Mortal Wkly Rep*. 2020;69:161–5. DOI: 10.15585/mmwr.mm6906a3.
41. Markowitz JT, Butler DA, Volkeneing LK, et al. Brief screening tool for disordered eating in diabetes: Internal consistency and external validity in a contemporary sample of pediatric patients with type 1 diabetes. *Diabetes Care*. 2010;33:495–500. DOI: 10.2337/dc09-1890.
42. Kann L, Kinchen SA, Williams BI, et al. Youth risk behavior surveillance—United States, 1999. State and local YRBSS Coordinators. *J Sch Health*. 2000;70:271–85. DOI: 10.1111/j.1746-1561.2000.tb07252.x.
43. Goldschmidt AB, Doyle AC, Wilfley DE. Assessment of binge eating in overweight youth using a questionnaire version of the child eating disorder examination with instructions. *Int J Eat Disord*. 2007;40:460–7. DOI: 10.1002/eat.20387.
44. Stice E, Telch CF, Rizvi SL. Development and validation of the eating disorder diagnostic scale: A brief self-report measure of anorexia, bulimia, and binge-eating disorder. *Psychol Assess*. 2000;12:123–31. DOI: 10.1037//1040-3590.12.2.123.
45. Zuijdwyk CS, Pardy SA, Dowden JJ, et al. The mSCOFF for screening disordered eating in pediatric type 1 diabetes. *Diabetes Care*. 2014;37:e26–7. DOI: 10.2337/dc13-1637.
46. Morgan JF, Reid F, Lacey JH. The SCOFF questionnaire: Assessment of a new screening tool for eating disorders. *BMJ*. 1999;319:1467–8. DOI: 10.1136/bmj.319.7223.1467.
47. Chamay-Weber C, Combescurc C, Lanza L, et al. Screening obese adolescents for binge eating disorder in primary care: The Adolescent Binge Eating Scale. *J Pediatr*. 2017;185:68–72. DOI: 10.1016/j.jpeds.2017.02.038.
48. Franklin EV, Simpson V, Berthet-Miron M, et al. A pilot study evaluating a binge-eating screener in children: Development of the Children's Brief Binge-Eating Questionnaire in a pediatric obesity clinic. *Clin Pediatr (Phila)*. 2019;58:1063–71. DOI: 10.1177/0009922819863664.
49. Lebow J, Narr C, Matkka A, et al. Engaging primary care providers in managing pediatric eating disorders: A mixed methods study. *J Eat Disord*. 2021;9:11. DOI: 10.1186/s40337-020-00363-8.
50. Ma C, Gonzales-Pacheco D, Cerami J, Coakley KE. Emergency medicine physicians' knowledge and perceptions of training, education, and resources in eating disorders. *J Eat Disord*. 2021;9:4. DOI: 10.1186/s40337-020-00355-8.
51. Johns G, Taylor B, John A, Tan J. Current eating disorder healthcare services - The perspectives and experiences of individuals with eating disorders, their families and health professionals: Systematic review and thematic synthesis. *BIPsych Open*. 2019;5:e59. DOI: 10.1192/bjo.2019.48.
52. Hayashi D, Edwards C, Emond JA, et al. What is food noise? A conceptual model of food cue reactivity. *Nutrients*. 2023;15:4809. DOI: 10.3390/nu15224809.
53. Li SS, Kalan RE, Smith A, et al. Momentary mechanisms of binge-eating symptoms using ecological momentary assessment: The moderating role of food addiction. *Eur Eat Disord Rev*. 2024;32:1105–16. DOI: 10.1002/erv.3116.
54. Aoun L, Almaridini S, Saliba F, et al. GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)? A systematic review. *J Clin Transl Endocrinol*. 2024;35:100333. DOI: 10.1016/j.jcte.2024.100333.
55. Jebelle H, Danielsen YS, Sumithran P, et al. GLP-1 receptor agonist medications for obesity and type 2 diabetes treatment: A rapid review of changes in eating behaviors and eating disorder risk. *Obes Rev*. 2026;27:e70049. DOI: 10.1111/obr.70049.
56. Bartel S, McElroy SL, Levangie D, Keshen A. Use of glucagon-like peptide-1 receptor agonists in eating disorder populations. *Int J Eat Disord*. 2024;57:286–93. DOI: 10.1002/eat.24109.
57. Coniglio KA, Becker KR, Franko DL, et al. Won't stop or can't stop? Food restriction as a habitual behavior among individuals with anorexia nervosa or atypical anorexia nervosa. *Eat Behav*. 2017;26:144–7. DOI: 10.1016/j.eatbeh.2017.03.005.
58. Peyyety V, Jankowski M, Apte S, et al. Youth perspectives on the use of medications for weight loss. *J Adolesc Health*. 2025;77:262–8. DOI: 10.1016/j.jadohealth.2025.02.011.
59. Chivare R, Schoemer P, Ragavan MI, et al. Primary care perspectives on prescribing anti-obesity medication for adolescents. *Pediatr Obes*. 2024;19:e13146. DOI: 10.1111/lipo.13146.
60. Nehushtan H, Elrajabi R, Peyyety V, et al. Weight loss medications in youth: Decision-making experiences, eating behaviors, and uncertainty about endpoint. *J Adolesc Health*. 2026;79:265–72. DOI: 10.1016/j.jadohealth.2026.03.017.
61. American Diabetes Association Professional Practice Committee. 14. Children and adolescents: Standards of care in diabetes—2026. *Diabetes Care*. 2026;49:S297–320. DOI: 10.2337/dc26-S014.
62. Gordon K, Matthews A, Zeller MH, Lin J. Practical guidelines for eating disorder risk mitigation in patients undergoing obesity treatment for the pediatric provider. *Curr Opin Pediatr*. 2024;36:367–74. DOI: 10.1097/MOP.0000000000001356.
63. Tomiyama AJ, Carr D, Granberg EM, et al. How and why weight stigma drives the obesity "epidemic" and harms health. *BMC Med*. 2018;16:123. DOI: 10.1186/s12916-018-1116-5.
64. Phelan SM, Burgess DJ, Yeazel MW, et al. Impact of weight bias and stigma on quality of care and outcomes for patients with obesity. *Obes Rev*. 2015;16:319–26. DOI: 10.1111/obr.12266.